Prognostic implications of N6-methyladenosine RNA regulators in breast cancer
The significance of N 6 -methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators an...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 12; číslo 1; s. 1222 - 19 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
24.01.2022
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The significance of N
6
-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. |
|---|---|
| AbstractList | The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. Abstract The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy.The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. The significance of N 6 -methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy. |
| ArticleNumber | 1222 |
| Author | Wang, Linbang Yan, Ziqiang Guo, Hao Tai, Jiaojiao Liu, Jingkun |
| Author_xml | – sequence: 1 givenname: Jiaojiao surname: Tai fullname: Tai, Jiaojiao organization: Department of Orthopedics, Honghui Hospital, Xi’an Jiaotong University – sequence: 2 givenname: Linbang surname: Wang fullname: Wang, Linbang organization: Department of Orthopedic Surgery, The First Affiliated Hospital, Chongqing Medical University – sequence: 3 givenname: Hao surname: Guo fullname: Guo, Hao organization: Department of Orthopedics, Honghui Hospital, Xi’an Jiaotong University – sequence: 4 givenname: Ziqiang surname: Yan fullname: Yan, Ziqiang email: heluxue68@hotmail.com organization: Department of Orthopedics, Honghui Hospital, Xi’an Jiaotong University – sequence: 5 givenname: Jingkun surname: Liu fullname: Liu, Jingkun email: 1768697234@qq.com organization: Department of Orthopedics, Honghui Hospital, Xi’an Jiaotong University |
| BookMark | eNp9UU1vFSEUnZgaW2v_gKtJ3LgZ5XtgY9I0WpvUaoyuCQOXKS_z4Akzpv330jeN2i7KBu7lnMO5nJfNQUwRmuY1Ru8wovJ9YZgr2SFCOsQx4d3Ns-aIIMY7Qgk5-O982JyUskF1caIYVi-aQ8pRz7Hoj5ov33IaYypzsG3Y7qZgzRxSLG3y7ZXotjBf307GQYWECO33q9M2w7hMZk65tCG2QwZT5taaaCG_ap57MxU4ud-Pm5-fPv44-9xdfj2_ODu97Cxj_dxJDwSDIh6w4MYRIlQt1eCoFIo4JLzyFAxwIgxHjkvPxdAPzDEy9Haw9Li5WHVdMhu9y2Fr8q1OJuh9I-VRm1xHmkBT6QUyngnhGRNUDZTb2qJMEucMwlXrw6q1W4YtOAtxzmZ6IPrwJoZrPabfWvZSSE6rwNt7gZx-LVBmvQ3FwjSZCGkpmog6IFc1jgp98wi6SUuO9av2KCo5oqyiyIqyOZWSwf81g5G-C1-v4esavt6Hr28qST4i2TDvs6ymw_Q0la7UUt-JI-R_rp5g_QE7usTc |
| CitedBy_id | crossref_primary_10_1002_mc_23661 crossref_primary_10_1016_j_jri_2023_104160 crossref_primary_10_1002_ijc_34900 crossref_primary_10_3390_molecules29010140 |
| Cites_doi | 10.1093/jnci/85.15.1206 10.1186/s12943-020-01170-0 10.1038/s41467-019-12801-6 10.18632/oncotarget.15170 10.1038/ncomms3612 10.1158/1078-0432.ccr-11-0072 10.1186/s12943-019-1084-1 10.1002/hep.27558 10.18632/aging.202163 10.1038/s41418-019-0461-z 10.18632/aging.101856 10.1016/j.ccell.2020.10.019 10.1038/s41568-018-0010-y 10.7150/ijbs.39046 10.1172/jci67428 10.18632/oncotarget.15736 10.1684/abc.2016.1192 10.1159/000430499 10.1186/1471-2105-11-602 10.1517/14728222.2011.636739 10.7150/ijbs.18834 10.1002/cam4.1722 10.3389/fonc.2019.00332 10.1093/nar/gkaa048 10.3389/fendo.2018.00396 10.1111/febs.13614 10.1038/s41416-018-0137-3 10.1016/j.ejphar.2021.174401 10.3389/fbioe.2018.00089 10.1038/s41586-019-0916-x 10.1038/s41523-019-0133-7 10.1186/s13045-019-0805-7 10.1111/jcmm.15104 10.1016/j.taap.2017.02.012 10.1371/journal.pntd.0006683 10.1186/s12943-020-1146-4 10.1186/s12943-019-1038-7 10.3389/fimmu.2019.02693 10.14670/hh-11-916 10.1155/2018/2584243 10.3322/caac.21412 10.1186/s13058-018-1079-7 10.1146/annurev-cellbio-100616-060758 10.1126/science.aar3593 10.1016/j.bbagrm.2016.02.010 10.1038/onc.2011.393 10.1016/j.cell.2018.05.060 10.7150/jca.35053 10.1038/s41416-019-0539-x 10.1016/j.intimp.2019.105932 10.1631/jzus.B1400221 10.1016/j.jval.2017.04.021 10.2147/cmar.s202342 10.1016/j.semcancer.2017.11.003 10.1038/srep04002 10.2147/bctt.s109847 10.1186/s12885-019-5538-z 10.1001/jamaoncol.2018.4942 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-022-05125-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 19 |
| ExternalDocumentID | oai_doaj_org_article_38f60af466f44639b35c8f63482dda01 PMC8786853 10_1038_s41598_022_05125_x |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c447t-8fe21e92fe165ad22691e99bd38692d06f9f3eae526a50d58f56b7b4d42b7cbc3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000746700700066&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Fri Oct 03 12:50:38 EDT 2025 Tue Nov 04 01:57:43 EST 2025 Thu Oct 02 09:49:17 EDT 2025 Tue Oct 07 07:45:36 EDT 2025 Sat Nov 29 02:51:17 EST 2025 Tue Nov 18 21:00:39 EST 2025 Fri Feb 21 02:39:20 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c447t-8fe21e92fe165ad22691e99bd38692d06f9f3eae526a50d58f56b7b4d42b7cbc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/38f60af466f44639b35c8f63482dda01 |
| PMID | 35075167 |
| PQID | 2622385034 |
| PQPubID | 2041939 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_38f60af466f44639b35c8f63482dda01 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8786853 proquest_miscellaneous_2622659045 proquest_journals_2622385034 crossref_primary_10_1038_s41598_022_05125_x crossref_citationtrail_10_1038_s41598_022_05125_x springer_journals_10_1038_s41598_022_05125_x |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-24 |
| PublicationDateYYYYMMDD | 2022-01-24 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | LiuTThe m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translationNucleic Acids Res.202048381638311:CAS:528:DC%2BB3cXisVKlur%2FO10.1093/nar/gkaa048319969157144925 JiangLExploring diagnostic m6A regulators in endometriosisAging20201225916259381:CAS:528:DC%2BB3MXmsF2qtbo%3D10.18632/aging.202163332322737803542 PassaroAStenzingerAPetersSTumor mutational burden as a pan-cancer biomarker for immunotherapy: The limits and potential for convergenceCancer Cell2020386246251:CAS:528:DC%2BB3cXitlemtbjJ10.1016/j.ccell.2020.10.01933171127 HammerlDBreast cancer genomics and immuno-oncological markers to guide immune therapiesSemin. Cancer Biol.2018521781881:CAS:528:DC%2BC2sXhslymt7zI10.1016/j.semcancer.2017.11.00329104025 UenoTGenome-wide copy number analysis in primary breast cancerExpert Opin. Ther. Targets201216Suppl 1S31351:CAS:528:DC%2BC38XivFOnu74%3D10.1517/14728222.2011.63673922313367 ZhiXβII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatinHepatology (Baltimore, MD)2015615986121:CAS:528:DC%2BC2MXhsV2nu78%3D10.1002/hep.27558 LiuZXLiLMSunHLLiuSMLink between m6A modification and cancersFront. Bioeng. Biotechnol.201868910.3389/fbioe.2018.00089300620936055048 ZhuangZDiagnostic, progressive and prognostic performance of m(6)A methylation RNA regulators in lung adenocarcinomaInt. J. Biol. Sci.202016178517971:CAS:528:DC%2BB3cXhvVCgsL%2FI10.7150/ijbs.39046323989497211177 CohenRAssociation of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency statusJAMA Oncol.2019555155510.1001/jamaoncol.2018.494230452494 McVeighTPKerinMJClinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancerBreast Cancer (Dove Medical Press)201793934001:CAS:528:DC%2BC1cXit1Sks7rJ10.2147/bctt.s109847 WuHSPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21Eur. J. Pharmacol.202110.1016/j.ejphar.2021.17440134973190 ModiSHSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabClin. Cancer Res.201117513251391:CAS:528:DC%2BC3MXpsFSksbw%3D10.1158/1078-0432.ccr-11-007221558407 CheriyathVG1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancerOncogene201231222222361:CAS:528:DC%2BC38Xmt1WnsLk%3D10.1038/onc.2011.39321996729 YuSTargeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancerInt. J. Biol. Sci.20171350551710.7150/ijbs.18834285294585436570 ChengNCs1, a Clonorchis sinensis-derived serodiagnostic antigen containing tandem repeats and a signal peptidePLoS Negl. Trop. Dis.2018121:CAS:528:DC%2BC1MXhslejsbvF10.1371/journal.pntd.0006683300709876091968 JeffriesCDPerkinsDOGuanXGene processing control loops suggested by sequencing, splicing, and RNA foldingBMC Bioinform.2010116021:CAS:528:DC%2BC3MXmtFM%3D10.1186/1471-2105-11-602 WuLWuDNingJLiuWZhangDChanges of N6-methyladenosine modulators promote breast cancer progressionBMC Cancer20191932610.1186/s12885-019-5538-z309534736451293 LiTMETTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinomaMol. Cancer2019181121:CAS:528:DC%2BC1MXht1Kks7bF10.1186/s12943-019-1038-7312305926589893 LeeHNeurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3pBiochem. Biophys. Acta.1859599–61120161:CAS:528:DC%2BC28Xjt1ykt7s%3D10.1016/j.bbagrm.2016.02.010 GuCMettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1Mol. Cancer2019181681:CAS:528:DC%2BC1MXisVSlsbvJ10.1186/s12943-019-1084-1317609406876123 ShiYYTHDF1 links hypoxia adaptation and non-small cell lung cancer progressionNat. Commun.20191048922019NatCo..10.4892S1:CAS:528:DC%2BC1MXitVKrsbvM10.1038/s41467-019-12801-6316538496814821 HuXIGF2BP2 regulates DANCR by serving as an N6-methyladenosine readerCell Death Differ.201910.1038/s41418-019-0461-z318191577244716 LiHHigh expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltrationJ. Cell Mol. Med.202024445244651:CAS:528:DC%2BB3cXnslKqtbo%3D10.1111/jcmm.15104321764257176877 Aponte-LópezAFuentes-PananáEMCortes-MuñozDMuñoz-CruzSMast cell, the neglected member of the tumor microenvironment: Role in breast cancerJ. Immunol. Res.2018201825842431:CAS:528:DC%2BC1cXit1Glu7rL10.1155/2018/2584243296514405832101 ZhangBm(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancerMol. Cancer202019531:CAS:528:DC%2BB3cXlslGitrs%3D10.1186/s12943-020-01170-0321647507066851 GhaffariAIntravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancerBreast Cancer Res. (BCR)2019211210.1186/s13058-018-1079-7 ChoiJGyamfiJJangHKooJSThe role of tumor-associated macrophage in breast cancer biologyHistol. Histopathol.2018331331451:CAS:528:DC%2BC1MXhtlGmsLs%3D10.14670/hh-11-91628681373 PrabhuSEnhanced effect of geldanamycin nanocomposite against breast cancer cells growing in vitro and as xenograft with vanquished normal cell toxicityToxicol. Appl. Pharmacol.201732060721:CAS:528:DC%2BC2sXjsVGqs70%3D10.1016/j.taap.2017.02.01228213093 AziziESingle-cell map of diverse immune phenotypes in the breast tumor microenvironmentCell201817412931308.e12361:CAS:528:DC%2BC1cXht1Cis7vN10.1016/j.cell.2018.05.060299615796348010 QuanCEzrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocationCancer Manag. Res.201911655365661:CAS:528:DC%2BB3cXkvVOitbo%3D10.2147/cmar.s202342313720566634270 DuanJWangYJiaoSCheckpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challengesCancer Med.201874517452910.1002/cam4.1722300883476144152 BhattaraiSMachine learning-based prediction of breast cancer growth rate in vivoBr. J. Cancer201912149750410.1038/s41416-019-0539-x313959506738119 YoshiharaKInferring tumour purity and stromal and immune cell admixture from expression dataNat. Commun.2013426122013NatCo...4.2612Y1:CAS:528:DC%2BC3sXhs1Oqu7zP10.1038/ncomms361224113773 ZhaoXPrognostic significance of tumor-associated macrophages in breast cancer: A meta-analysis of the literatureOncotarget20178305763058610.18632/oncotarget.15736284271655444766 LiuZJSemenzaGLZhangHFHypoxia-inducible factor 1 and breast cancer metastasisJ. Zhejiang Univ. Sci. B20151632431:CAS:528:DC%2BC2MXhtlWjsLY%3D10.1631/jzus.B1400221255599534288942 XuFZhangHChenJLinLChenYImmune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinomaInt. Immunopharmacol.2020811:CAS:528:DC%2BC1MXitlOgtLnE10.1016/j.intimp.2019.10593231836430 DengXSuRStanfordSChenJCritical enzymatic functions of FTO in obesity and cancerFront. Endocrinol.2018939610.3389/fendo.2018.00396 CheriyathVG1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROSBr. J. Cancer201811952641:CAS:528:DC%2BC1cXhtF2htb3J10.1038/s41416-018-0137-3298993946035266 GaspariniGPozzaFHarrisALEvaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patientsJ. Natl Cancer Inst.199385120612191:STN:280:DyaK3szitlWnsA%3D%3D10.1093/jnci/85.15.12068331681 LiuLN6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survivalJ. Cancer201910544754591:CAS:528:DC%2BB3cXovVyltrY%3D10.7150/jca.35053316324896775703 BylerSGenetic and epigenetic aspects of breast cancer progression and therapyAnticancer Res.201434107110771:CAS:528:DC%2BC2cXotVSnur8%3D24596345 HallPSValue of information analysis of multiparameter tests for chemotherapy in early breast cancer: The OPTIMA prelim trialValue Health2017201311131810.1016/j.jval.2017.04.02129241890 MaityADasBN6-methyladenosine modification in mRNA: Machinery, function and implications for health and diseasesFEBS J.2016283160716301:CAS:528:DC%2BC28XhvFWrug%3D%3D10.1111/febs.1361426645578 AndradeSSInterface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - Influence of platelets and fibrin bundles on the behavior of breast tumor cellsOncotarget20178168511687410.18632/oncotarget.15170281874345370006 HanDAnti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cellsNature20195662702742019Natur.566..270H1:CAS:528:DC%2BC1MXmt1ynsr0%3D10.1038/s41586-019-0916-x307285046522227 YangXMETTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XISTMol. Cancer202019461:CAS:528:DC%2BB3cXkvValtb4%3D10.1186/s12943-020-1146-4321112137047419 DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A. & Jemal, A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J. Clin.67, 439–448. https://doi.org/10.3322/caac.21412 (2017). AlexiaCPolyoxidonium(®) activates cytotoxic lymphocyte responses through dendritic cell maturation: Clinical effects in breast cancerFront. Immunol.20191026931:CAS:528:DC%2BB3cXhsVCgsbnP10.3389/fimmu.2019.02693318499346892947 Gu-TrantienCCD4+ follicular helper T cell infiltration predicts breast cancer survivalJ. Clin. Investig.2013123287328921:CAS:528:DC%2BC3sXhtFWjtr3J10.1172/jci67428237781403696556 LimBWoodwardWAWangXReubenJMUenoNTInflammatory breast cancer biology: The tumour microenvironment is keyNat. Rev. Cancer2018184854991:CAS:528:DC%2BC1cXosFylsLo%3D10.1038/s41568-018-0010-y29703913 SoysalSDTzankovAMuenstSERole of the tumor microenvironment in breast cancerPathobiolo L Jiang (5125_CR41) 2020; 12 R Cohen (5125_CR58) 2019; 5 D Hammerl (5125_CR4) 2018; 52 KD Meyer (5125_CR8) 2017; 33 PS Hall (5125_CR40) 2017; 20 D Han (5125_CR17) 2019; 566 A Aponte-López (5125_CR33) 2018; 2018 SD Soysal (5125_CR11) 2015; 82 S Yu (5125_CR29) 2017; 13 N Cheng (5125_CR53) 2018; 12 S Prabhu (5125_CR28) 2017; 320 Y Shi (5125_CR46) 2019; 10 S Ma (5125_CR23) 2019; 12 C Quan (5125_CR49) 2019; 11 J Zhou (5125_CR45) 2019; 11 A Roulot (5125_CR37) 2016; 74 C Alexia (5125_CR34) 2019; 10 X Zhi (5125_CR54) 2015; 61 Z Liu (5125_CR2) 2014; 4 X Yang (5125_CR26) 2020; 19 Z Zhuang (5125_CR56) 2020; 16 S Byler (5125_CR5) 2014; 34 R Cristescu (5125_CR9) 2018 V Cheriyath (5125_CR51) 2012; 31 J Duan (5125_CR10) 2018; 7 H Li (5125_CR42) 2020; 24 K Yoshihara (5125_CR57) 2013; 4 E Azizi (5125_CR12) 2018; 174 L Wu (5125_CR20) 2019; 19 B Zhang (5125_CR16) 2020; 19 V Cheriyath (5125_CR52) 2018; 119 H Wu (5125_CR55) 2021 B Lim (5125_CR31) 2018; 18 J Choi (5125_CR35) 2018; 33 C Gu (5125_CR22) 2019; 18 TP McVeigh (5125_CR39) 2017; 9 T Ueno (5125_CR44) 2012; 16 X Hu (5125_CR25) 2019 G Gasparini (5125_CR3) 1993; 85 ZJ Liu (5125_CR13) 2015; 16 5125_CR1 X Deng (5125_CR27) 2018; 9 T Liu (5125_CR18) 2020; 48 H Lee (5125_CR50) 1859; 599–611 S Modi (5125_CR30) 2011; 17 A Maity (5125_CR6) 2016; 283 A Ghaffari (5125_CR48) 2019; 21 C Gu-Trantien (5125_CR32) 2013; 123 SS Andrade (5125_CR14) 2017; 8 T Li (5125_CR24) 2019; 18 S Bhattarai (5125_CR38) 2019; 121 F Xu (5125_CR43) 2020; 81 X Zhao (5125_CR36) 2017; 8 ZX Liu (5125_CR7) 2018; 6 L Liu (5125_CR21) 2019; 10 ME Gatti-Mays (5125_CR15) 2019; 5 A Passaro (5125_CR59) 2020; 38 CD Jeffries (5125_CR19) 2010; 11 Y Bai (5125_CR47) 2019; 9 |
| References_xml | – reference: LimBWoodwardWAWangXReubenJMUenoNTInflammatory breast cancer biology: The tumour microenvironment is keyNat. Rev. Cancer2018184854991:CAS:528:DC%2BC1cXosFylsLo%3D10.1038/s41568-018-0010-y29703913 – reference: HallPSValue of information analysis of multiparameter tests for chemotherapy in early breast cancer: The OPTIMA prelim trialValue Health2017201311131810.1016/j.jval.2017.04.02129241890 – reference: YoshiharaKInferring tumour purity and stromal and immune cell admixture from expression dataNat. Commun.2013426122013NatCo...4.2612Y1:CAS:528:DC%2BC3sXhs1Oqu7zP10.1038/ncomms361224113773 – reference: CohenRAssociation of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency statusJAMA Oncol.2019555155510.1001/jamaoncol.2018.494230452494 – reference: HuXIGF2BP2 regulates DANCR by serving as an N6-methyladenosine readerCell Death Differ.201910.1038/s41418-019-0461-z318191577244716 – reference: BhattaraiSMachine learning-based prediction of breast cancer growth rate in vivoBr. J. Cancer201912149750410.1038/s41416-019-0539-x313959506738119 – reference: PassaroAStenzingerAPetersSTumor mutational burden as a pan-cancer biomarker for immunotherapy: The limits and potential for convergenceCancer Cell2020386246251:CAS:528:DC%2BB3cXitlemtbjJ10.1016/j.ccell.2020.10.01933171127 – reference: MaityADasBN6-methyladenosine modification in mRNA: Machinery, function and implications for health and diseasesFEBS J.2016283160716301:CAS:528:DC%2BC28XhvFWrug%3D%3D10.1111/febs.1361426645578 – reference: Aponte-LópezAFuentes-PananáEMCortes-MuñozDMuñoz-CruzSMast cell, the neglected member of the tumor microenvironment: Role in breast cancerJ. Immunol. Res.2018201825842431:CAS:528:DC%2BC1cXit1Glu7rL10.1155/2018/2584243296514405832101 – reference: BaiYYTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinomaFront. Oncol.2019933210.3389/fonc.2019.00332311312576509179 – reference: AndradeSSInterface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - Influence of platelets and fibrin bundles on the behavior of breast tumor cellsOncotarget20178168511687410.18632/oncotarget.15170281874345370006 – reference: CheriyathVG1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROSBr. J. Cancer201811952641:CAS:528:DC%2BC1cXhtF2htb3J10.1038/s41416-018-0137-3298993946035266 – reference: ModiSHSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabClin. Cancer Res.201117513251391:CAS:528:DC%2BC3MXpsFSksbw%3D10.1158/1078-0432.ccr-11-007221558407 – reference: DengXSuRStanfordSChenJCritical enzymatic functions of FTO in obesity and cancerFront. Endocrinol.2018939610.3389/fendo.2018.00396 – reference: BylerSGenetic and epigenetic aspects of breast cancer progression and therapyAnticancer Res.201434107110771:CAS:528:DC%2BC2cXotVSnur8%3D24596345 – reference: GhaffariAIntravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancerBreast Cancer Res. (BCR)2019211210.1186/s13058-018-1079-7 – reference: JeffriesCDPerkinsDOGuanXGene processing control loops suggested by sequencing, splicing, and RNA foldingBMC Bioinform.2010116021:CAS:528:DC%2BC3MXmtFM%3D10.1186/1471-2105-11-602 – reference: ShiYYTHDF1 links hypoxia adaptation and non-small cell lung cancer progressionNat. Commun.20191048922019NatCo..10.4892S1:CAS:528:DC%2BC1MXitVKrsbvM10.1038/s41467-019-12801-6316538496814821 – reference: WuLWuDNingJLiuWZhangDChanges of N6-methyladenosine modulators promote breast cancer progressionBMC Cancer20191932610.1186/s12885-019-5538-z309534736451293 – reference: LiuZZhangXSZhangSBreast tumor subgroups reveal diverse clinical prognostic powerSci. Rep.2014440021:CAS:528:DC%2BC2cXjtFajur4%3D10.1038/srep04002244998685379255 – reference: LiTMETTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinomaMol. Cancer2019181121:CAS:528:DC%2BC1MXht1Kks7bF10.1186/s12943-019-1038-7312305926589893 – reference: MaSThe interplay between m6A RNA methylation and noncoding RNA in cancerJ. Hematol. Oncol.2019121211:CAS:528:DC%2BC1MXit1arsb%2FJ10.1186/s13045-019-0805-7317572216874823 – reference: PrabhuSEnhanced effect of geldanamycin nanocomposite against breast cancer cells growing in vitro and as xenograft with vanquished normal cell toxicityToxicol. Appl. Pharmacol.201732060721:CAS:528:DC%2BC2sXjsVGqs70%3D10.1016/j.taap.2017.02.01228213093 – reference: McVeighTPKerinMJClinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancerBreast Cancer (Dove Medical Press)201793934001:CAS:528:DC%2BC1cXit1Sks7rJ10.2147/bctt.s109847 – reference: UenoTGenome-wide copy number analysis in primary breast cancerExpert Opin. Ther. Targets201216Suppl 1S31351:CAS:528:DC%2BC38XivFOnu74%3D10.1517/14728222.2011.63673922313367 – reference: MeyerKDJaffreySRRethinking m(6)A readers, writers, and erasersAnnu. Rev. Cell Dev. Biol.2017333193421:CAS:528:DC%2BC2sXht1GitbvL10.1146/annurev-cellbio-100616-060758287592565963928 – reference: AlexiaCPolyoxidonium(®) activates cytotoxic lymphocyte responses through dendritic cell maturation: Clinical effects in breast cancerFront. Immunol.20191026931:CAS:528:DC%2BB3cXhsVCgsbnP10.3389/fimmu.2019.02693318499346892947 – reference: LeeHNeurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3pBiochem. Biophys. Acta.1859599–61120161:CAS:528:DC%2BC28Xjt1ykt7s%3D10.1016/j.bbagrm.2016.02.010 – reference: GaspariniGPozzaFHarrisALEvaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patientsJ. Natl Cancer Inst.199385120612191:STN:280:DyaK3szitlWnsA%3D%3D10.1093/jnci/85.15.12068331681 – reference: YuSTargeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancerInt. J. Biol. Sci.20171350551710.7150/ijbs.18834285294585436570 – reference: ZhaoXPrognostic significance of tumor-associated macrophages in breast cancer: A meta-analysis of the literatureOncotarget20178305763058610.18632/oncotarget.15736284271655444766 – reference: QuanCEzrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocationCancer Manag. Res.201911655365661:CAS:528:DC%2BB3cXkvVOitbo%3D10.2147/cmar.s202342313720566634270 – reference: WuHSPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21Eur. J. Pharmacol.202110.1016/j.ejphar.2021.17440134973190 – reference: SoysalSDTzankovAMuenstSERole of the tumor microenvironment in breast cancerPathobiology J. Immunopathol. Mol. Cell. Biol.2015821421521:CAS:528:DC%2BC2MXhsFWnsb%2FN10.1159/000430499 – reference: LiuLN6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survivalJ. Cancer201910544754591:CAS:528:DC%2BB3cXovVyltrY%3D10.7150/jca.35053316324896775703 – reference: LiuZJSemenzaGLZhangHFHypoxia-inducible factor 1 and breast cancer metastasisJ. Zhejiang Univ. Sci. B20151632431:CAS:528:DC%2BC2MXhtlWjsLY%3D10.1631/jzus.B1400221255599534288942 – reference: YangXMETTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XISTMol. Cancer202019461:CAS:528:DC%2BB3cXkvValtb4%3D10.1186/s12943-020-1146-4321112137047419 – reference: LiHHigh expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltrationJ. Cell Mol. Med.202024445244651:CAS:528:DC%2BB3cXnslKqtbo%3D10.1111/jcmm.15104321764257176877 – reference: ZhangBm(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancerMol. Cancer202019531:CAS:528:DC%2BB3cXlslGitrs%3D10.1186/s12943-020-01170-0321647507066851 – reference: DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A. & Jemal, A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J. Clin.67, 439–448. https://doi.org/10.3322/caac.21412 (2017). – reference: JiangLExploring diagnostic m6A regulators in endometriosisAging20201225916259381:CAS:528:DC%2BB3MXmsF2qtbo%3D10.18632/aging.202163332322737803542 – reference: HammerlDBreast cancer genomics and immuno-oncological markers to guide immune therapiesSemin. Cancer Biol.2018521781881:CAS:528:DC%2BC2sXhslymt7zI10.1016/j.semcancer.2017.11.00329104025 – reference: ChoiJGyamfiJJangHKooJSThe role of tumor-associated macrophage in breast cancer biologyHistol. Histopathol.2018331331451:CAS:528:DC%2BC1MXhtlGmsLs%3D10.14670/hh-11-91628681373 – reference: XuFZhangHChenJLinLChenYImmune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinomaInt. Immunopharmacol.2020811:CAS:528:DC%2BC1MXitlOgtLnE10.1016/j.intimp.2019.10593231836430 – reference: HanDAnti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cellsNature20195662702742019Natur.566..270H1:CAS:528:DC%2BC1MXmt1ynsr0%3D10.1038/s41586-019-0916-x307285046522227 – reference: CheriyathVG1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancerOncogene201231222222361:CAS:528:DC%2BC38Xmt1WnsLk%3D10.1038/onc.2011.39321996729 – reference: RoulotATumoral heterogeneity of breast cancerAnn. Biol. Clin.20167465366010.1684/abc.2016.1192 – reference: GuCMettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1Mol. Cancer2019181681:CAS:528:DC%2BC1MXisVSlsbvJ10.1186/s12943-019-1084-1317609406876123 – reference: LiuZXLiLMSunHLLiuSMLink between m6A modification and cancersFront. Bioeng. Biotechnol.201868910.3389/fbioe.2018.00089300620936055048 – reference: DuanJWangYJiaoSCheckpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challengesCancer Med.201874517452910.1002/cam4.1722300883476144152 – reference: ZhuangZDiagnostic, progressive and prognostic performance of m(6)A methylation RNA regulators in lung adenocarcinomaInt. J. Biol. Sci.202016178517971:CAS:528:DC%2BB3cXhvVCgsL%2FI10.7150/ijbs.39046323989497211177 – reference: ZhiXβII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatinHepatology (Baltimore, MD)2015615986121:CAS:528:DC%2BC2MXhsV2nu78%3D10.1002/hep.27558 – reference: LiuTThe m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translationNucleic Acids Res.202048381638311:CAS:528:DC%2BB3cXisVKlur%2FO10.1093/nar/gkaa048319969157144925 – reference: AziziESingle-cell map of diverse immune phenotypes in the breast tumor microenvironmentCell201817412931308.e12361:CAS:528:DC%2BC1cXht1Cis7vN10.1016/j.cell.2018.05.060299615796348010 – reference: ZhouJGene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - A retrospective study using TCGA databaseAging201911163316471:CAS:528:DC%2BC1MXitl2qur7F10.18632/aging.101856308772656461179 – reference: Gu-TrantienCCD4+ follicular helper T cell infiltration predicts breast cancer survivalJ. Clin. Investig.2013123287328921:CAS:528:DC%2BC3sXhtFWjtr3J10.1172/jci67428237781403696556 – reference: CristescuRPan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyScience (New York, NY)201810.1126/science.aar3593 – reference: ChengNCs1, a Clonorchis sinensis-derived serodiagnostic antigen containing tandem repeats and a signal peptidePLoS Negl. Trop. Dis.2018121:CAS:528:DC%2BC1MXhslejsbvF10.1371/journal.pntd.0006683300709876091968 – reference: Gatti-MaysMEIf we build it they will come: Targeting the immune response to breast cancerNPJ. Breast Cancer20195371:CAS:528:DC%2BC1MXitVKrur3I10.1038/s41523-019-0133-7317009936820540 – volume: 85 start-page: 1206 year: 1993 ident: 5125_CR3 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/85.15.1206 – volume: 19 start-page: 53 year: 2020 ident: 5125_CR16 publication-title: Mol. Cancer doi: 10.1186/s12943-020-01170-0 – volume: 10 start-page: 4892 year: 2019 ident: 5125_CR46 publication-title: Nat. Commun. doi: 10.1038/s41467-019-12801-6 – volume: 8 start-page: 16851 year: 2017 ident: 5125_CR14 publication-title: Oncotarget doi: 10.18632/oncotarget.15170 – volume: 4 start-page: 2612 year: 2013 ident: 5125_CR57 publication-title: Nat. Commun. doi: 10.1038/ncomms3612 – volume: 17 start-page: 5132 year: 2011 ident: 5125_CR30 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.ccr-11-0072 – volume: 18 start-page: 168 year: 2019 ident: 5125_CR22 publication-title: Mol. Cancer doi: 10.1186/s12943-019-1084-1 – volume: 61 start-page: 598 year: 2015 ident: 5125_CR54 publication-title: Hepatology (Baltimore, MD) doi: 10.1002/hep.27558 – volume: 12 start-page: 25916 year: 2020 ident: 5125_CR41 publication-title: Aging doi: 10.18632/aging.202163 – year: 2019 ident: 5125_CR25 publication-title: Cell Death Differ. doi: 10.1038/s41418-019-0461-z – volume: 11 start-page: 1633 year: 2019 ident: 5125_CR45 publication-title: Aging doi: 10.18632/aging.101856 – volume: 38 start-page: 624 year: 2020 ident: 5125_CR59 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.10.019 – volume: 18 start-page: 485 year: 2018 ident: 5125_CR31 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-018-0010-y – volume: 16 start-page: 1785 year: 2020 ident: 5125_CR56 publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.39046 – volume: 123 start-page: 2873 year: 2013 ident: 5125_CR32 publication-title: J. Clin. Investig. doi: 10.1172/jci67428 – volume: 8 start-page: 30576 year: 2017 ident: 5125_CR36 publication-title: Oncotarget doi: 10.18632/oncotarget.15736 – volume: 74 start-page: 653 year: 2016 ident: 5125_CR37 publication-title: Ann. Biol. Clin. doi: 10.1684/abc.2016.1192 – volume: 82 start-page: 142 year: 2015 ident: 5125_CR11 publication-title: Pathobiology J. Immunopathol. Mol. Cell. Biol. doi: 10.1159/000430499 – volume: 11 start-page: 602 year: 2010 ident: 5125_CR19 publication-title: BMC Bioinform. doi: 10.1186/1471-2105-11-602 – volume: 16 start-page: S31 issue: Suppl 1 year: 2012 ident: 5125_CR44 publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2011.636739 – volume: 13 start-page: 505 year: 2017 ident: 5125_CR29 publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.18834 – volume: 7 start-page: 4517 year: 2018 ident: 5125_CR10 publication-title: Cancer Med. doi: 10.1002/cam4.1722 – volume: 9 start-page: 332 year: 2019 ident: 5125_CR47 publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00332 – volume: 48 start-page: 3816 year: 2020 ident: 5125_CR18 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkaa048 – volume: 9 start-page: 396 year: 2018 ident: 5125_CR27 publication-title: Front. Endocrinol. doi: 10.3389/fendo.2018.00396 – volume: 34 start-page: 1071 year: 2014 ident: 5125_CR5 publication-title: Anticancer Res. – volume: 283 start-page: 1607 year: 2016 ident: 5125_CR6 publication-title: FEBS J. doi: 10.1111/febs.13614 – volume: 119 start-page: 52 year: 2018 ident: 5125_CR52 publication-title: Br. J. Cancer doi: 10.1038/s41416-018-0137-3 – year: 2021 ident: 5125_CR55 publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2021.174401 – volume: 6 start-page: 89 year: 2018 ident: 5125_CR7 publication-title: Front. Bioeng. Biotechnol. doi: 10.3389/fbioe.2018.00089 – volume: 566 start-page: 270 year: 2019 ident: 5125_CR17 publication-title: Nature doi: 10.1038/s41586-019-0916-x – volume: 5 start-page: 37 year: 2019 ident: 5125_CR15 publication-title: NPJ. Breast Cancer doi: 10.1038/s41523-019-0133-7 – volume: 12 start-page: 121 year: 2019 ident: 5125_CR23 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-019-0805-7 – volume: 24 start-page: 4452 year: 2020 ident: 5125_CR42 publication-title: J. Cell Mol. Med. doi: 10.1111/jcmm.15104 – volume: 320 start-page: 60 year: 2017 ident: 5125_CR28 publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2017.02.012 – volume: 12 year: 2018 ident: 5125_CR53 publication-title: PLoS Negl. Trop. Dis. doi: 10.1371/journal.pntd.0006683 – volume: 19 start-page: 46 year: 2020 ident: 5125_CR26 publication-title: Mol. Cancer doi: 10.1186/s12943-020-1146-4 – volume: 18 start-page: 112 year: 2019 ident: 5125_CR24 publication-title: Mol. Cancer doi: 10.1186/s12943-019-1038-7 – volume: 10 start-page: 2693 year: 2019 ident: 5125_CR34 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.02693 – volume: 33 start-page: 133 year: 2018 ident: 5125_CR35 publication-title: Histol. Histopathol. doi: 10.14670/hh-11-916 – volume: 2018 start-page: 2584243 year: 2018 ident: 5125_CR33 publication-title: J. Immunol. Res. doi: 10.1155/2018/2584243 – ident: 5125_CR1 doi: 10.3322/caac.21412 – volume: 21 start-page: 12 year: 2019 ident: 5125_CR48 publication-title: Breast Cancer Res. (BCR) doi: 10.1186/s13058-018-1079-7 – volume: 33 start-page: 319 year: 2017 ident: 5125_CR8 publication-title: Annu. Rev. Cell Dev. Biol. doi: 10.1146/annurev-cellbio-100616-060758 – year: 2018 ident: 5125_CR9 publication-title: Science (New York, NY) doi: 10.1126/science.aar3593 – volume: 599–611 start-page: 2016 year: 1859 ident: 5125_CR50 publication-title: Biochem. Biophys. Acta. doi: 10.1016/j.bbagrm.2016.02.010 – volume: 31 start-page: 2222 year: 2012 ident: 5125_CR51 publication-title: Oncogene doi: 10.1038/onc.2011.393 – volume: 174 start-page: 1293 year: 2018 ident: 5125_CR12 publication-title: Cell doi: 10.1016/j.cell.2018.05.060 – volume: 10 start-page: 5447 year: 2019 ident: 5125_CR21 publication-title: J. Cancer doi: 10.7150/jca.35053 – volume: 121 start-page: 497 year: 2019 ident: 5125_CR38 publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0539-x – volume: 81 year: 2020 ident: 5125_CR43 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2019.105932 – volume: 16 start-page: 32 year: 2015 ident: 5125_CR13 publication-title: J. Zhejiang Univ. Sci. B doi: 10.1631/jzus.B1400221 – volume: 20 start-page: 1311 year: 2017 ident: 5125_CR40 publication-title: Value Health doi: 10.1016/j.jval.2017.04.021 – volume: 11 start-page: 6553 year: 2019 ident: 5125_CR49 publication-title: Cancer Manag. Res. doi: 10.2147/cmar.s202342 – volume: 52 start-page: 178 year: 2018 ident: 5125_CR4 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2017.11.003 – volume: 4 start-page: 4002 year: 2014 ident: 5125_CR2 publication-title: Sci. Rep. doi: 10.1038/srep04002 – volume: 9 start-page: 393 year: 2017 ident: 5125_CR39 publication-title: Breast Cancer (Dove Medical Press) doi: 10.2147/bctt.s109847 – volume: 19 start-page: 326 year: 2019 ident: 5125_CR20 publication-title: BMC Cancer doi: 10.1186/s12885-019-5538-z – volume: 5 start-page: 551 year: 2019 ident: 5125_CR58 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2018.4942 |
| SSID | ssj0000529419 |
| Score | 2.3774996 |
| Snippet | The significance of N
6
-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role... The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and... Abstract The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential... |
| SourceID | doaj pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1222 |
| SubjectTerms | 631/67/1347 631/67/580 Bioinformatics Breast cancer Copy number Genes Humanities and Social Sciences Immune response Immunotherapy Inactivation Invasiveness Metastases Microenvironments multidisciplinary N6-methyladenosine Polymerase chain reaction Reverse transcription Science Science (multidisciplinary) Tumor microenvironment Tumors |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFNyJQkJG4gdXEr9gnVBAVF1YrBFJvlp-wUpWUZIvaf8_YyW7ZSvTCMbGTTDwznrFnPB9Cb9om2ZhaDprmEuHKCqJ8oMSGOsBUGJOoUwGbaBcLdXysl_OG2zinVW7mxDJRh97nPfIDKsGQKVEz_v70F8moUTm6OkNo3ES3cpUEVlL3lts9lhzF4o2ez8rUTB2MYK_ymTJYgYE0UkHOd-xRKdu_42tezZS8Ei4tVujo_v_S_wDdm_1PfDgJzEN0I3aP0J0JkfLiMfqyHPqcegetePVXsjnuE15IkvGmL05syBXGwT3FXxeHeJjQ7PthxKsOu5zkvsY-C9PwBH0_-vTt42cyIy4Qz3m7JipF2kRNU2yksAFcMw2X2gWmpKahlkknFm0UVFpRB6GSkK51PHDqWu88e4r2ur6LzxAGV1GHukkOXsF9bR2MoXCxpUz4JqhYoWYz7sbP5cgzKsaJKWFxpszEKwO8MoVX5rxCb7fPnE7FOK7t_SGzc9szF9IuN_rhh5n10jCVZG0TlzLBwphpB-TBrVzyJwRbNxXa37DTzNo9mkteVuj1thn0MgdbbBf7s6mPFBqGoULtjhDtELTb0q1-lgrfqlUS_KgKvduI2-XH__3Dz6-n9QW6S4vgN4TyfbS3Hs7iS3Tb_16vxuFV0Zw_eW4iQA priority: 102 providerName: ProQuest |
| Title | Prognostic implications of N6-methyladenosine RNA regulators in breast cancer |
| URI | https://link.springer.com/article/10.1038/s41598-022-05125-x https://www.proquest.com/docview/2622385034 https://www.proquest.com/docview/2622659045 https://pubmed.ncbi.nlm.nih.gov/PMC8786853 https://doaj.org/article/38f60af466f44639b35c8f63482dda01 |
| Volume | 12 |
| WOSCitedRecordID | wos000746700700066&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest-Biological Science customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-6q-BF_MTqOkTwpmXbNJ_HXdlFD1PKojCeStIkOLC0S2dWdv97X5LOOLOgXrw8aJO2yct7zS_k5fcQei9Kr50XFDzN-JxKzXLZWZJrW1j4FTrPCh-TTYi6louFanZSfYWYsEQPnBR3XEnPC-0p5x5WLpUyFevgVuBksVank1uAenYWU4nVmyhaqumUTFHJ4xXMVOE0Gay9wA4Jy2_2ZqJI2L-HMu_GSN7ZKI3zz_kT9HgCjvgkNfgpuuf6Z-hhSiV5-xzNm3EIMXNQipc7UeJ48LjmeUgUfXupbaAGB1yJL-oTPKY09MO4wssemxCdvsZdsILxBfp2fvb10-d8SpWQd5SKdS69I6VTxLuSM20BUym4VMZWkitiC-6Vr5x2jHDNCsukZ9wIQy0lRnSmq16ig37o3SuEAeMpW5TewCtoV2gDKmDGCQKKL610GSo3amu7iUc8pLO4bON-diXbpOoWVN1GVbc3GfqwfeYqsWj8tfZpGI1tzcCAHW-AXbSTXbT_sosMHW3Gsp3cctUSDmhIsqKiGXq3LQaHCrskunfDdarDmQI1ZEjs2cBeg_ZL-uWPSM0theQAgDL0cWMtvz_-5w6__h8dfoMekWjdZU7oETpYj9fuLXrQ_VwvV-MM3RcLEaWcocPTs7q5mEWXATknTZAC5GHzZd58_wXjGBqk |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoILb0SggJHgBFETx3acA0LlUbVqu1qhIvXmxrFdVqqSkt1C90_xGxk7yZatRG89cIztJI79zXicGc8H8DpPXWldzlDStIuZLHksK0Pj0iQGVaF1PHGBbCIfjeTBQTFegd_DWRgfVjnoxKCoTVP5f-TrVOBCJnmSsQ8nP2LPGuW9qwOFRgeLHTv_hVu26fvtzzi_byjd_LL_aSvuWQXiirF8FktnaWoL6mwqeGnQ_CjwstAmk6KgJhGucJktLaei5Inh0nGhc80MozqvdJXhc6_BdTQjqAyhguPFPx3vNWNp0Z_NSTK5PsX10Z9hwx0fop_y-Gxp_Qs0AUu27cXIzAvu2bDqbd7938brHtzp7Wuy0QnEfVix9QO42TFuzh_C3rhtfGgh1pLJX8H0pHFkJGLPpz0_Lo3PoI7mN_k62iCtPfIUZ007JZOaaB_EPyOVF5b2EXy7km95DKt1U9snQNAULkySOo2PYFVSapwzrm1OM16lRtoI0mGeVdWnW_esH8cquP0zqTpsKMSGCthQZxG8Xdxz0iUbubT1Rw-fRUufKDwUNO2R6vWOyqQTSemYEA43_lmhsXtY5FMaGVMmaQRrA3xUr72m6hw7EbxaVKPe8c6ksrbNaddG8AKHIYJ8CbRLHVquqSffQwZzmUuBdmIE7wZ4n7_83x_89PK-voRbW_t7u2p3e7TzDG7TIHRpTNkarM7aU_scblQ_Z5Np-yJILYHDq4b9H4dLgEs |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8hAX3ohAgSDBCaJNHNtxDggVyoqqsFohkHozdmyXlaqkZLfQ_Wv8OsZOsmUr0VsPHGM7iR_fjMf2eD6A50XmlHUFRUnTLqFCsURUhiTKpAZVoXUsdYFsophMxP5-Od2A38NdGO9WOejEoKhNU_k98hHhOJEJluZ05Hq3iOnO-M3Rj8QzSPmT1oFOo4PInl3-wuXb_PXuDo71C0LG77-8-5D0DANJRWmxSISzJLMlcTbjTBk0RUp8LLXJBS-JSbkrXW6VZYQrlhomHOO60NRQootKVzl-9xJcLnzQ8uA2OF3t7_gTNJqV_T2dNBejOc6V_j4brv5QEghLTtbmwkAZsGbnnvXSPHNUG2bA8c3_ue9uwY3e7o63O0G5DRu2vgNXOybO5V34NG0b73KIufHsLyf7uHHxhCeeZ3t5qIyPrI5mefx5sh239sBTnzXtPJ7VsfbO_Yu48kLU3oOvF9KW-7BZN7V9ADGayKVJM6fxE7RKlcbxY9oWJGdVZoSNIBvGXFZ9GHbPBnIogztALmSHE4k4kQEn8iSCl6t3jrogJOeWfuuhtCrpA4iHhKY9kL0-krlwPFWOcu4oRStVY_UwyYc6MkalWQRbA5Rkr9Xm8hRHETxbZaM-8odMqrbNcVeGsxK7IYJiDcBrFVrPqWffQ2RzUQiO9mMErwaon_783w1-eH5dn8I1RLv8uDvZewTXSZC_LCF0CzYX7bF9DFeqn4vZvH0SBDiGbxeN-j8RlYkI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+implications+of+N6-methyladenosine+RNA+regulators+in+breast+cancer&rft.jtitle=Scientific+reports&rft.au=Tai%2C+Jiaojiao&rft.au=Wang%2C+Linbang&rft.au=Guo%2C+Hao&rft.au=Yan%2C+Ziqiang&rft.date=2022-01-24&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-05125-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_022_05125_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |